Gilbert's syndrome explained

Gilbert's syndrome
Synonyms:Gilbert syndrome, Meulengracht syndrome, Gilbert-Lereboullet syndrome, hyperbilirubinemia Arias type, hyperbilirubinemia type 1, familial cholemia, familial nonhemolytic jaundice
Speciality:Gastroenterology
Symptoms:Usually none, still, abdominal pain, nausea, tired and weak feeling, slight jaundice may present
Complications:Usually none
Causes:Genetic
Differential:Crigler–Najjar syndrome, Rotor syndrome, Dubin–Johnson syndrome
Treatment:None typically needed
Frequency:~5%

Gilbert syndrome (GS) is a syndrome in which the liver of affected individuals processes bilirubin more slowly than the majority.[1] Many people never have symptoms.[1] Occasionally jaundice (a slight yellowish color of the skin or whites of the eyes) may occur.[1]

Gilbert syndrome is due to a genetic variant in the UGT1A1 gene which results in decreased activity of the bilirubin uridine diphosphate glucuronosyltransferase enzyme.[1] It is typically inherited in an autosomal recessive pattern and occasionally in an autosomal dominant pattern depending on the type of variant. Episodes of jaundice may be triggered by stress such as exercise, menstruation, or not eating.[2] Diagnosis is based on higher levels of unconjugated bilirubin in the blood without either signs of other liver problems or red blood cell breakdown.[3] [2]

Typically no treatment is needed.[1] Gilbert syndrome is associated with decreased cardiovascular health risks. If jaundice is significant phenobarbital may be used, which aids in the conjugation of bilirubin.[1] Gilbert syndrome affects about 5% of people in the United States.[2] Males are more often diagnosed than females.[1] It is often not noticed until late childhood to early adulthood.[3] The condition was first described in 1901 by Augustin Nicolas Gilbert.[3] [4]

Signs and symptoms

Jaundice

Gilbert syndrome produces an elevated level of unconjugated bilirubin in the bloodstream, but normally has no consequences. Mild jaundice may appear under conditions of exertion, stress, fasting, and infections, but the condition is otherwise usually asymptomatic.[5] [6] Severe cases are seen by yellowing of the skin tone and yellowing of the conjunctiva in the eye.[7]

Gilbert syndrome has been reported to contribute to an accelerated onset of neonatal jaundice. The syndrome cannot cause severe indirect hyperbilirubinemia in neonates by itself, but it may have a summative effect on rising bilirubin when combined with other factors,[8] for example in the presence of increased red blood cell destruction due to diseases such as G6PD deficiency.[9] [10] This situation can be especially dangerous if not quickly treated, as the high serum bilirubin can cause irreversible neurological disability in the form of kernicterus.[11] [12] [13]

Detoxification of certain drugs

The enzymes that are defective in GS – UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) – are also responsible for some of the liver's ability to detoxify certain drugs. For example, Gilbert syndrome is associated with severe diarrhea and neutropenia in patients who are treated with irinotecan, which is metabolized by UGT1A1.[14]

While paracetamol (acetaminophen) is not metabolized by UGT1A1,[15] it is metabolized by one of the other enzymes also deficient in some people with GS.[16] [17] A subset of people with GS may have an increased risk of paracetamol toxicity.[17]

Cardiovascular effects

The mild increase in unconjugated bilirubin due to Gilbert syndrome is closely related to the reduction in the prevalence of chronic diseases, especially cardiovascular disease and type 2 diabetes, related risk factors, and all-cause mortality.[18] Observational studies emphasize that the antioxidant effects of unconjugated bilirubin may bring survival benefits to patients.[19]

Several analyses have found a significantly decreased risk of coronary artery disease (CAD) in individuals with GS.[20] [21]

Specifically, people with mildly elevated levels of bilirubin (1.1 mg/dl to 2.7 mg/dl) were at lower risk for CAD and at lower risk for future heart disease.[22] These researchers went on to perform a meta-analysis of data available up to 2002, and confirmed the incidence of atherosclerotic disease (hardening of the arteries) in subjects with GS had a close and inverse relationship to the serum bilirubin. This beneficial effect was attributed to bilirubin IXα which is recognized as a potent antioxidant, rather than confounding factors such as high-density lipoprotein levels.[22]

This association was also seen in long-term data from the Framingham Heart Study.[23] [24] Moderately elevated levels of bilirubin in people with GS and the (TA)7/(TA)7 genotype were associated with one-third the risk for both coronary heart disease and cardiovascular disease as compared to those with the (TA)6/(TA)6 genotype (i.e. a normal, nonmutated gene locus).

Platelet counts and MPV (mean platelet volume) are decreased in patients with Gilbert's syndrome. The elevated levels of bilirubin and decreasing levels of MPV and CRP in Gilbert's syndrome patients may have an effect on the slowing down of the atherosclerotic process.[25]

Other

Symptoms, whether connected or not to GS, have been reported in a subset of those affected: fatigue (feeling tired all the time), difficulty maintaining concentration, unusual patterns of anxiety, loss of appetite, nausea, abdominal pain, loss of weight, itching (with no rash), and others,[26] such as humor change or depression. But scientific studies found no clear pattern of adverse symptoms related to the elevated levels of unconjugated bilirubin in adults. However, other substances glucuronidized by the affected enzymes in those with Gilbert's syndrome could theoretically, at their toxic levels, cause these symptoms.[27] [28] Consequently, debate exists about whether GS should be classified as a disease.[27] [29] However, Gilbert syndrome has been linked to an increased risk of gallstones.[26] [30]

Cause

Mutations in the UGT1A1 gene lead to Gilbert Syndrome.[31] The gene provides instructions for making the bilirubin uridine diphosphate glucuronosyltransferase (bilirubin-UGT) enzyme, which can be found in the liver cells and is responsible for preparing bilirubin for removal from the body.[32]

The bilirubin-UGT enzyme performs a chemical reaction called glucuronidation. Glucuronic acid is transferred to unconjugated bilirubin, which is a yellowish pigment made when your body breaks down old red blood cells,[33] and then being converted to conjugated bilirubin during the reaction. Conjugated bilirubin passes from the liver into the intestines with bile. It's then excreted in stool.

People with Gilbert syndrome have approximately 30 percent of normal bilirubin-UGT enzyme function, which contributes to a lower rate of glucuronidation of unconjugated bilirubin. This substance then accumulates in the body, causing mild hyperbilirubinemia.[32]

Genetics

Gilbert syndrome is a phenotypic effect, mostly associated with increased blood bilirubin levels, but also sometimes characterized by mild jaundice due to increased unconjugated bilirubin, that arises from several different genotypic variants of the gene for the enzyme responsible for changing bilirubin to the conjugated form.

Gilbert's syndrome is characterized by a 70–80% reduction in the glucuronidation activity of the enzyme (UGT1A1). The UGT1A1 gene is located on human chromosome 2.[34]

More than 100 polymorphisms of the UGT1A1 gene are known, designated as UGT1A1*n (where n is the general chronological order of discovery), either of the gene itself or of its promoter region. UGT1A1 is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A(TA)6TAA; this variant accounts for about 50% of alleles in many populations. However, several allelic polymorphic variants of this region occur, the most common of which results from adding another dinucleotide repeat TA to the promoter region, resulting in A(TA)7TAA, which is called UGT1A1*28; this common variant accounts for about 40% of alleles in some populations, but is seen less often, around 3% of alleles, in Southeast and East Asian people and Pacific Islanders.

In most populations, Gilbert syndrome is most commonly associated with homozygous A(TA)7TAA alleles.[35] [36] [37] In 94% of GS cases, two other glucuronosyltransferase enzymes, UGT1A6 (rendered 50% inactive) and UGT1A7 (rendered 83% ineffective), are also affected.

However, Gilbert syndrome can arise without TATA box promoter polymorphic variants; in some populations, particularly healthy Southeast and East Asians, Gilbert's syndrome is more often a consequence of heterozygote missense mutations (such as Gly71Arg also known as UGT1A1*6, Tyr486Asp also known as UGT1A1*7, Pro364Leu also known as UGT1A1*73) in the actual gene coding region, which may be associated with significantly higher bilirubin levels.

Because of its effects on drug and bilirubin breakdown and because of its genetic inheritance, Gilbert's syndrome can be classed as a minor inborn error of metabolism.

Diagnosis

People with GS predominantly have elevated unconjugated bilirubin, while conjugated bilirubin is usually within the normal range or is less than 20% of the total. Levels of bilirubin in GS patients are reported to be from 20 μM to 90 μM (1.2 to 5.3 mg/dl) compared to the normal amount of < 20 μM. GS patients have a ratio of unconjugated/conjugated (indirect/direct) bilirubin commensurately higher than those without GS.

The level of total bilirubin is often further increased if the blood sample is taken after fasting for two days,[38] and a fast can, therefore, be useful diagnostically. A further conceptual step that is rarely necessary or appropriate is to give a low dose of phenobarbital:[39] the bilirubin will decrease substantially.

Tests can also detect DNA variants of UGT1A1 by polymerase chain reaction or DNA fragment sequencing.

Differential diagnosis

While Gilbert syndrome is considered harmless, it is clinically important because it may give rise to a concern about a blood or liver condition, which could be more dangerous. However, these conditions have additional indicators:

Treatment

Typically no treatment is needed.[1] If jaundice is significant phenobarbital may be used.[1]

Research directions

Vitamin levels

Studies conducted so far suggest that subjects with GS may have lower levels of vitamin D and folic acid than control subjects, having these levels inversely correlated with bilirubin levels. It may be that GS may impair the metabolism or absorption of these vitamins, or that these vitamins may affect the expression or activity of the UGT1A1 enzyme that is responsible for bilirubin conjugation. However, these studies had limitations, such as the small sample size, the lack of a standardized definition of GS, the possible confounding factors of diet, lifestyle, and medication use, and the cross-sectional and observational design that does not allow for causal inference.[41]

The role of bilirubin in health and disease

Ongoing studies suggest that mild hyperbilirubinaemia in GS may have beneficial effects, probably due to the antioxidant and anti-inflammatory properties of bilirubin. Hyperbilirubinaemia in GS may protect against oxidative stress and inflammation-related diseases, such as cardiovascular diseases, cancers, diabetes, and neurodegenerative disorders. However, the mechanisms and pathways of bilirubin protection are not fully elucidated, and the optimal level and range of bilirubin are unknown. The genetic and environmental factors that influence UGT1A1 expression and activity are also poorly characterized and may affect the variability and penetrance of GS. Despite the fact that hyperbilirubinemia in GS is associated with reduced incidence of cardiovascular diseases,[42] diabetes, and metabolic syndrome,[43] the clinical significance and implications of these GS research findings are unclear, and can not yet be translated into preventive or therapeutic strategies.[44]

History

Gilbert syndrome was first described by French gastroenterologist Augustin Nicolas Gilbert and co-workers in 1901.[4] [45] In German literature, it is commonly associated with Jens Einar Meulengracht.

Alternative, less common names for this disorder include:

Society and culture

Notable cases

External links

Notes and References

  1. Web site: Gilbert syndrome. GARD. 2 July 2017. en. 2016. live. https://web.archive.org/web/20170804052908/https://rarediseases.info.nih.gov/diseases/6507/gilbert-syndrome. 4 August 2017.
  2. Web site: Gilbert syndrome. Genetics Home Reference. 2 July 2017. en. 27 June 2017. live. https://web.archive.org/web/20170627221429/https://ghr.nlm.nih.gov/condition/gilbert-syndrome. 27 June 2017.
  3. Web site: Gilbert Syndrome. NORD (National Organization for Rare Disorders). 2 July 2017. 2015. live. https://web.archive.org/web/20170220165114/https://rarediseases.org/rare-diseases/gilbert-syndrome/. 20 February 2017.
  4. Web site: Whonamedit – dictionary of medical eponyms. www.whonamedit.com. 2 July 2017. en. live. https://web.archive.org/web/20160918015240/http://www.whonamedit.com/synd.cfm/2877.html. 18 September 2016.
  5. Kasper et al., Harrison's Principles of Internal Medicine, 16th edition, McGraw-Hill 2005
  6. Boon et al., Davidson's Principles & Practice of Medicine, 20th edition, Churchill Livingstone 2006
  7. Web site: Philadelphia. The Children's Hospital of. 2014-08-23. Hyperbilirubinemia and Jaundice. 2022-02-17. www.chop.edu. en. 2022-02-17. https://web.archive.org/web/20220217090215/https://www.chop.edu/conditions-diseases/hyperbilirubinemia-and-jaundice. live.
  8. 21403409. 2011. Saki. F.. Hemmati. F.. Haghighat. M.. Prevalence of Gilbert syndrome in parents of neonates with pathologic indirect hyperbilirubinemia. Annals of Saudi Medicine. 31. 2. 140–4. 10.4103/0256-4947.77498. 3102472 . free .
  9. Bancroft JD, Kreamer B, Gourley GR . Gilbert syndrome accelerates development of neonatal jaundice . Journal of Pediatrics . 132 . 4 . 656–60 . 1998 . 9580766 . 10.1016/S0022-3476(98)70356-7.
  10. Cappellini MD, Di Montemuros FM, Sampietro M, Tavazzi D, Fiorelli G . The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels . British Journal of Haematology . 104 . 4 . 928–9 . 1999 . 10192462 . 10.1111/j.1365-2141.1999.1331a.x. 40300539 . free .
  11. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives. 2018. 10.2147/RRN.S125758. Usman. Fatima. Diala. Udochukwu. Shapiro. Steven. Le Pichon. Jean-Baptiste. Slusher. Tina. Research and Reports in Neonatology. 8. 33–44. free. 2020-07-15. 2020-08-13. https://web.archive.org/web/20200813152457/https://www.dovepress.com/acute-bilirubin-encephalopathy-and-its-progression-to-kernicterus-curr-peer-reviewed-article-RRN. live.
  12. Learning from claims: hyperbilirubinaemia and kernicterus. 2019. 10.1136/archdischild-2017-314622. Rennie. Janet M.. Beer. Jeanette. Upton. Michele. Archives of Disease in Childhood - Fetal and Neonatal Edition. 104. 2. F202–F204. 29802103. 6580733. 2020-07-15. 2020-07-15. https://web.archive.org/web/20200715192936/https://fn.bmj.com/content/104/2/F202. live.
  13. Book: Kernicterus . 2021 . StatPearls . 32644546 . Reddy . D. K. . Pandey . S. . 2020-07-15 . 2021-08-28 . https://web.archive.org/web/20210828093238/https://www.ncbi.nlm.nih.gov/books/NBK559120/ . live .
  14. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M . UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer . Br J Cancer . 91 . 4 . 678–82 . 2004 . 15280927 . 10.1038/sj.bjc.6602042 . 2364770.
  15. Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J . Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype . Int J Clin Pharmacol Ther . 42 . 2 . 73–7 . 2004 . 15180166 . 10.5414/cpp42073.
  16. Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW . Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians . Biochem Pharmacol . 65 . 9 . 1521–7 . 2003 . 12732365 . 10.1016/S0006-2952(03)00074-1.
  17. Esteban A, Pérez-Mateo M . 27543027 . Heterogeneity of paracetamol metabolism in Gilbert's syndrome . European Journal of Drug Metabolism and Pharmacokinetics . 24 . 1 . 9–13 . 1999 . 10412886 . 10.1007/BF03190005.
  18. 29390925. 2018. Wagner. K. H.. Shiels. R. G.. Lang. C. A.. Seyed Khoei. N.. Bulmer. A. C.. Diagnostic criteria and contributors to Gilbert's syndrome. Critical Reviews in Clinical Laboratory Sciences. 55. 2. 129–139. 10.1080/10408363.2018.1428526. 46870015. free.
  19. Overview of Gilbert's syndrome. 30709860. 2019. King. D.. Armstrong. M. J.. Drug and Therapeutics Bulletin. 57. 2. 27–31. 10.1136/dtb.2018.000028. 73447592. 2021-02-17. 2021-05-23. https://web.archive.org/web/20210523221721/https://pubmed.ncbi.nlm.nih.gov/30709860/. live.
  20. Ladislav Novotnýc . Libor Vítek . 43486067 . Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies . Experimental Biology and Medicine . 5. 568–571 . 2003 . 12709588 . 228 . 10.1177/15353702-0322805-29.
  21. Schwertner Harvey A . Vítek Libor . Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin . Atherosclerosis . 198 . 1 . 1–11 . May 2008 . 18343383 . 10.1016/j.atherosclerosis.2008.01.001 . Review . 2018-09-01 . 2018-09-04 . https://web.archive.org/web/20180904052440/https://zenodo.org/record/1258770 . live .
  22. Vítek L . Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels . Atherosclerosis . 160 . 2 . 449–56 . 2002. 11849670 . 10.1016/S0021-9150(01)00601-3 . Jirsa M . Brodanová M . etal .
  23. Lin JP . Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study . Circulation . 114 . 1476–81 . 2006 . 17000907 . 10.1161/CIRCULATIONAHA.106.633206 . 14. O'Donnell CJ . Schwaiger JP . etal . free .
  24. Bulmer. A. C.. Verkade. H. J.. Wagner. K.-H.. April 2013. Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Progress in Lipid Research. 52. 2. 193–205. 10.1016/j.plipres.2012.11.001. 1873-2194. 23201182. 10072/54228. free.
  25. Kundur. Avinash R.. Singh. Indu. Bulmer. Andrew C.. March 2015. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert's syndrome?. Atherosclerosis. 239. 1. 73–84. 10.1016/j.atherosclerosis.2014.12.042. 1879-1484. 25576848.
  26. http://www.gilbertssyndrome.com/ GilbertsSyndrome.com
  27. Olsson R, Bliding A, Jagenburg R, Lapidus L, Larsson B, Svärdsudd K, Wittboldt S . Gilbert's syndrome—does it exist? A study of the prevalence of symptoms in Gilbert syndrome . Acta Medica Scandinavica . 224 . 5 . 485–490 . 1988 . 3264448 . 10.1111/j.0954-6820.1988.tb19615.x.
  28. Bailey A, Robinson D, Dawson AM . 41989158 . Does Gilbert's disease exist? . Lancet . 1 . 931–3 . 1977 . 67389 . 10.1016/S0140-6736(77)92226-7 . 8018.
  29. Larissa K. F. Temple . Robin S. McLeod . Steven Gallinger . James G. Wright . Defining Disease in the Genomics Era . Science Magazine . 293 . 5531 . 807–808 . 2001 . 10.1126/science.1062938 . 11486074. 6520035 .
  30. del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A . Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis . Blood . 94 . 7 . 2259–62 . October 1999 . 10498597 . https://archive.today/20130414231815/http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&pmid=10498597 . dead . 2013-04-14 . 10.1182/blood.V94.7.2259.419k42_2259_2262 . 40558696 .
  31. Web site: Gilbert Syndrome . 2022-03-24 . NORD (National Organization for Rare Disorders) . en-US . 2017-02-20 . https://web.archive.org/web/20170220165114/https://rarediseases.org/rare-diseases/gilbert-syndrome/ . live .
  32. Web site: Gilbert syndrome: MedlinePlus Genetics . 2022-03-24 . medlineplus.gov . en . 2019-04-08 . https://web.archive.org/web/20190408003455/https://ghr.nlm.nih.gov/condition/gilbert-syndrome . live .
  33. Web site: Gilbert's syndrome - Symptoms and causes . 2022-03-24 . Mayo Clinic . en . 2017-11-08 . https://web.archive.org/web/20171108164024/https://www.mayoclinic.org/diseases-conditions/gilberts-syndrome/basics/definition/con-20024904 . live .
  34. Web site: Entrez Gene: UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1. live. https://web.archive.org/web/20101205081110/http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. 2010-12-05.
  35. Raijmakers MT, Jansen PL, Steegers EA, Peters WH . Association of human liver bilirubin UDP-glucuronyltransferase activity, most commonly due to a polymorphism in the promoter region of the UGT1A1 gene. Journal of Hepatology. 2000. 33. 3. 348–351. 11019988. 10.1016/S0168-8278(00)80268-8.
  36. Bosma PJ . The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome . New England Journal of Medicine. 333 . 18 . 1171–5 . 1995 . 7565971 . 10.1056/NEJM199511023331802. Chowdhury JR . Bakker C . Gantla S . de Boer A . Oostra BA . Lindhout D . Tytgat GN . Jansen PL . Oude Elferink RP . etal . free .
  37. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B . 24943762 . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome . Lancet . 347 . 9001 . 578–81 . 1996 . 8596320 . 10.1016/S0140-6736(96)91273-8.
  38. J L Gollan . C Bateman . B H Billing . Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome . Gut . 5. 335–340 . 1976 . 10.1136/gut.17.5.335 . 17 . 1278716 . 1411132.
  39. N Carulli . M Ponz de Leon . E Mauro . F Manenti . A Ferrari . Alteration of drug metabolism in Gilbert's syndrome . Gut . 8. 581–587 . 1976 . 10.1136/gut.17.8.581 . 17 . 976795 . 1411334.
  40. Book: StatPearls. Singh, A.. Koritala, J.. Jialal, I.. Unconjugated Hyperbilirubinemia. 20 May 2023. 21 December 2023. StatPearls Publishing. Treasure Island, Florida. 31747203. 18 November 2023. https://web.archive.org/web/20231118165105/http://www.ncbi.nlm.nih.gov/books/NBK549796/. live.
  41. Kamal S, Abdelhakam S, Ghoraba D, Massoud Y, Aziz KA, Hassan H, Hafez T, Abdel Sallam A . The frequency, clinical course, and health related quality of life in adults with Gilbert's syndrome: a longitudinal study . BMC Gastroenterol . 19 . 1 . 22 . February 2019 . 30717703 . 6360704 . 10.1186/s12876-019-0931-2 . free .
  42. Gorbunova O, Chernysheva E . A New Look at Gilbert Syndrome (Literature Review) . Russian . Georgian Med News . 296 . 75–81 . November 2019 . 31889709 .
  43. Adin CA . Bilirubin as a Therapeutic Molecule: Challenges and Opportunities . Antioxidants . 10 . 10 . September 2021 . 1536 . 34679671 . 8532879 . 10.3390/antiox10101536 . free .
  44. Vítek L, Tiribelli C . Gilbert's syndrome revisited . J Hepatol . 79 . 4 . 1049–1055 . October 2023 . 37390966 . 10.1016/j.jhep.2023.06.004 . 259303433 . free .
  45. Gilbert A, Lereboullet P . La cholémie simple familiale . La Semaine Médicale. 21 . 241–3 . 1901 .
  46. Foulk, WT . Butt, HR . Owen, CA Jr . Whitcomb, FF Jr . Mason, HL . Constitutional hepatic dysfunction (Gilbert's disease): its natural history and related syndromes . Medicine (Baltimore) . 38 . 1959 . 13632313 . 25–46 . 1. 10.1097/00005792-195902000-00002 . 8265932 . free .
  47. Book: Shmaefsky, Brian. Biotechnology 101. Greenwood Publishing Group. 2006. 175. 5. 978-0-313-33528-0. https://books.google.com/books?id=E4KhutqTYNAC&q=%22Arthur%20Kornberg%22%20gilbert&pg=PA175.
  48. News: Wire preaches delights of three cliffs. 2007-04-27. South Wales Evening Post. 3.
  49. News: David Cox. . A Tennis Player Learns to Be Aggressive for Health's Sake . New York Times . 19 April 2014 . Monte Carlo . live . https://web.archive.org/web/20161014010306/http://www.nytimes.com/2014/04/20/sports/tennis/tennis-roundup.html . 14 October 2016 .
  50. Web site: Illness that 'shut down' Tech3 MotoGP rookie Jonas Folger diagnosed . Khorounzhiy . Valentin . 2017-11-09 . Autosport.com . . 2017-11-09 . After visiting specialists in his native Germany, Folger has been diagnosed with Gilbert's syndrome – a genetic ailment that precludes the liver from correctly processing bilirubin. . 2017-11-10 . https://web.archive.org/web/20171110114518/https://www.autosport.com/motogp/news/132907/illness-that-hut-down-folger-diagnosed . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Gilbert's syndrome".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.